IRIDEX Corporation Asset Resilience Ratio
IRIDEX Corporation asset resilience ratio. IRIDEX Corporation (IRIX) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IRIX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of IRIDEX Corporation (1998–2017)
Asset resilience ratio of IRIDEX Corporation from 1998 to 2017. This chart shows how IRIDEX Corporation's Asset Resilience Ratio has changed over time. Read IRIDEX Corporation balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down IRIDEX Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IRIX asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: IRIDEX Corporation maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
IRIDEX Corporation Industry Peers by Asset Resilience Ratio
Compare IRIDEX Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
IRIDEX Corporation Asset Resilience Ratio by Year (1998–2017)
IRIDEX Corporation asset resilience ratio by year from 1998 to 2017. The table below shows the annual Asset Resilience Ratio data for IRIDEX Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $41.65 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $48.14 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $41.82 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $41.82 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $33.68 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $28.91 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $32.15 Million | -- |
| 2007-12-31 | 8.15% | $3.80 Million | $46.65 Million | -13.21pp |
| 2005-12-31 | 21.36% | $8.78 Million | $41.10 Million | +12.86pp |
| 2004-12-31 | 8.50% | $3.32 Million | $39.09 Million | -7.55pp |
| 2003-12-31 | 16.05% | $5.75 Million | $35.84 Million | +9.17pp |
| 2002-12-31 | 6.87% | $2.36 Million | $34.27 Million | -6.41pp |
| 2001-12-31 | 13.29% | $4.49 Million | $33.79 Million | +4.73pp |
| 2000-12-31 | 8.55% | $3.00 Million | $35.02 Million | -2.17pp |
| 1999-12-31 | 10.72% | $3.50 Million | $32.66 Million | -7.20pp |
| 1998-12-31 | 17.92% | $5.09 Million | $28.40 Million | -- |
About IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and Oc… Read more